Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment
Supak Yothaisong, Hasaya Dokduang, Naohiko Anzai, et al.
Tumor Biology (2017) Vol. 39, Iss. 3, pp. 101042831769454-101042831769454
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

The Human SLC7A5 (LAT1): The Intriguing Histidine/Large Neutral Amino Acid Transporter and Its Relevance to Human Health
Mariafrancesca Scalise, Michele Galluccio, Lara Console, et al.
Frontiers in Chemistry (2018) Vol. 6
Open Access | Times Cited: 236
Clinical development of metabolic inhibitors for oncology
Kathryn M. Lemberg, Sadakatali S. Gori, Takashi Tsukamoto, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 1
Open Access | Times Cited: 99
First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors
Naohiro Okano, Daisuke Naruge, Kirio Kawai, et al.
Investigational New Drugs (2020) Vol. 38, Iss. 5, pp. 1495-1506
Closed Access | Times Cited: 109
Amino acid transporters as emerging therapeutic targets in cancer
Yasuhiro Saito, Tomoyoshi Soga
Cancer Science (2021) Vol. 112, Iss. 8, pp. 2958-2965
Open Access | Times Cited: 68
SLC7A5 is required for cancer cell growth under arginine-limited conditions
Kyle Dunlap, Austin Bender, Alexis Bowles, et al.
Cell Reports (2025) Vol. 44, Iss. 1, pp. 115130-115130
Open Access | Times Cited: 1
The Regulation and Function of the L-Type Amino Acid Transporter 1 (LAT1) in Cancer
Travis B. Salisbury, Subha Arthur
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 8, pp. 2373-2373
Open Access | Times Cited: 81
Immunomodulatory role of branched-chain amino acids
Andrea Bonvini, Audrey Yule Coqueiro, Júlio Tirapegui, et al.
Nutrition Reviews (2018) Vol. 76, Iss. 11, pp. 840-856
Open Access | Times Cited: 63
Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation
Lili Quan, Ryuichi Ohgaki, Saori Hara, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 58
CD98 heavy chain as a prognostic biomarker and target for cancer treatment
Xia Pu, Anna Dubrovska
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 18
Branched‐Chain Amino Acids Deficiency Promotes Diabetic Neuropathic Pain Through Upregulating LAT1 and Inhibiting Kv1.2 Channel
Ze‐Yu Zhou, J. H. Wang, Zhixiao Li, et al.
Advanced Science (2024) Vol. 11, Iss. 33
Open Access | Times Cited: 8
GSE1 predicts poor survival outcome in gastric cancer patients by SLC7A5 enhancement of tumor growth and metastasis
Keshuo Ding, Sheng Tan, Xing Huang, et al.
Journal of Biological Chemistry (2018) Vol. 293, Iss. 11, pp. 3949-3964
Open Access | Times Cited: 50
A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1
Keisuke Enomoto, Fuyuki Sato, Shunji Tamagawa, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 49
Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma
Maihulan Maimaiti, Shinichi Sakamoto, Yasutaka Yamada, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 47
Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma
Kosuke Higuchi, Shinichi Sakamoto, Keisuke Ando, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 43
A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy
Junji Furuse, Masafumi Ikeda, Makoto Ueno, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 18, pp. 3990-3995
Closed Access | Times Cited: 6
L‐type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel‐resistant prostate cancer by inhibiting cyclin‐dependent kinase activity
Junryo Rii, Shinichi Sakamoto, Atsushi Mizokami, et al.
Cancer Science (2024) Vol. 115, Iss. 3, pp. 937-953
Open Access | Times Cited: 5
Glutamine transporters as pharmacological targets: From function to drug design
Mariafrancesca Scalise, Lorena Pochini, Michele Galluccio, et al.
Asian Journal of Pharmaceutical Sciences (2020) Vol. 15, Iss. 2, pp. 207-219
Open Access | Times Cited: 39
Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells
Kou Nishikubo, Ryuichi Ohgaki, Hiroki Okanishi, et al.
Journal of Cellular and Molecular Medicine (2022) Vol. 26, Iss. 20, pp. 5246-5256
Open Access | Times Cited: 22
Progress in research on the role of amino acid metabolic reprogramming in tumour therapy: A review
Dong Wang, Xin Wan
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113923-113923
Open Access | Times Cited: 20
Insights into the Transport Cycle of LAT1 and Interaction with the Inhibitor JPH203
Chiara Brunocilla, Lara Console, Filomena Rovella, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 4042-4042
Open Access | Times Cited: 13
Inhibition of cancer-type amino acid transporter LAT1 suppresses B16-F10 melanoma metastasis in mouse models
Zitong Shi, Kazuko Kaneda‐Nakashima, Ryuichi Ohgaki, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Exploring Amino Acid Transporters as Therapeutic Targets for Cancer: An Examination of Inhibitor Structures, Selectivity Issues, and Discovery Approaches
Sebastian Jakobsen, Carsten Uhd Nielsen
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 197-197
Open Access | Times Cited: 4
The LAT1 inhibitor JPH203 suppresses the growth of castration‐resistant prostate cancer through a CD24‐mediated mechanism
Shinpei Saito, Keisuke Ando, Shinichi Sakamoto, et al.
Cancer Science (2024) Vol. 115, Iss. 7, pp. 2461-2472
Open Access | Times Cited: 4
Multilayered proteomics reveals that JAM‐A promotes breast cancer progression via regulation of amino acid transporter LAT1
Kazufumi Magara, Akira Takasawa, Kumi Takasawa, et al.
Cancer Science (2024) Vol. 115, Iss. 9, pp. 3153-3168
Open Access | Times Cited: 4
The impact of epithelial-mesenchymal transition (EMT) induced by metabolic processes and intracellular signaling pathways on chemo-resistance, metastasis, and recurrence in solid tumors
Mahsa Liaghat, Saeid Ferdousmakan, Seyedeh Haniyeh Mortazavi, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top